LLY
Eli Lilly and Company
LLY has the edge over SNWV overall, supported by stronger fundamentals and stronger valuation.
SNWV
SANUWAVE Health Inc.
SNWV trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNWV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Strong |
SNWV's cash flow and balance sheet are currently healthy, and its profitability is stable, but its revenue is under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SNWV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 1.2x | $1.58 | — |
| Current | 4.3x | $1.58 | — |
| Cheap | 4.4x | $1.63 | +3.2% |
| Fair | 4.9x | $1.81 | +15% |
| Expensive | 5.7x | $2.10 | +33% |
Historical ranges are pointers, not guarantees.
SNWV has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SNWV on the outlook, with more favorable revenue expectations.
SNWV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SNWV's earnings to grow and its profitability to improve, but its revenue to decline.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus SNWV down 90%.
SNWV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.28 | +247% |
| Q3 2024 | $4.76 | +$31.01 |
| Q2 2024 | $0.00 | +$15.00 |
| Q1 2024 | -$3.75 | +$7.50 |
| Q4 2023 | -$11.25 | -$3.75 |
| Q3 2023 | -$26.25 | -$18.75 |
| Q2 2023 | -$15.00 | -$3.75 |
| Q1 2023 | -$11.25 | +$7.50 |
| Q4 2022 | -$7.50 | +$11.25 |
SNWV has returned to profit: it earned $0.37 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SNWV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SNWV on profitability, with a higher operating margin.
SNWV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.6M | -25% |
| Q2 2026 | $9.7M | -4.2% |
| Q1 2026 | $9.6M | +3% |
| Q4 2025 | $13.4M | +30% |
| Q3 2025 | $11.5M | +22% |
| Q2 2025 | $10.2M | +42% |
| Q1 2025 | $9.3M | +61% |
| Q4 2024 | $10.3M | +48% |
SNWV's revenue has held roughly level: $9M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | -25 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | -12% | -22 points |
| Q4 2025 | 15% | -9.5 points |
| Q3 2025 | 13% | -8.1 points |
| Q2 2025 | 18% | -9.3 points |
| Q1 2025 | 11% | +29 points |
| Q4 2024 | 24% | +9.6 points |
SNWV's operating margin was −13% last quarter, down 25 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SNWV on cash flow, with more consistent year-over-year improvement.
SNWV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -296% |
| Q2 2026 | $91K | +$257K |
| Q1 2026 | $374K | +$2.1M |
| Q4 2025 | $3.2M | +538% |
| Q3 2025 | $556K | -55% |
| Q2 2025 | -$166K | +$594K |
| Q1 2025 | -$1.7M | -270% |
| Q4 2024 | $505K | +$1.8M |
SNWV's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SNWV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.1K shares |
| 1 year | -5.9% | -538K shares |
| 3 years | +487% | +7.1M shares |
| 5 years | +739% | +7.6M shares |
SNWV has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SNWV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -8.0x | Net Cash |
| Q2 2026 | -2.8x | Net Cash |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q3 2024 | 0.9x | Very low |
SNWV has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SNWV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.2 | Oversold |
| Stochastic | 16.7 | Oversold |
SNWV's weekly RSI is 24 (oversold) and its Stochastic is 17 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SNWV PE vs Healthcare Sector
| Metric | SNWV | Sector median | Relative |
|---|---|---|---|
| PE | 4.3x | 26x | 83% below |
| PE % | 12 | 29 | 17 pts below |
SNWV has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SNWV on trend strength, trading above more of its moving averages.
SNWV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.32 | 63% below |
| 20 week MA | $5.42 | 71% below |
| 50 week MA | $15.2 | 90% below |
| 100 week MA | $23.5 | 93% below |
| 200 week MA | $16.3 | 90% below |
SNWV is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SNWV on returns for 2026, with the stronger performance.
SNWV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.9 | $79.7 | +29% |
| 2021 | $79.7 | $56.3 | -29% |
| 2022 | $56.3 | $10.5 | -81% |
| 2023 | $10.5 | $4.87 | -54% |
| 2024 | $4.87 | $23.0 | +371% |
| 2025 | $23.0 | $30.5 | +33% |
| 2026 YTD | $30.5 | $1.58 | -95% |
SNWV's yearly returns have swung widely, from +371% in 2024 to −81% in 2022. It's down 95% so far in 2026.